Dose Escalation of Jardiance (Empagliflozin)

Patient Selection and Monitoring

• Patients with diabetic kidney disease and eGFR ≥45 mL/min/1.73 m² do not require dose adjustment when increasing to 25 mg, according to the Mayo Clinic Proceedings 2
• The American College of Cardiology recommends monitoring for signs and symptoms of hypotension, genital mycotic infections, and other adverse effects after starting therapy, especially in patients with renal impairment, elderly patients, those with low systolic blood pressure, or patients on diuretics 1
• Glycemic control should be reassessed 4-8 weeks after dose escalation, as recommended by Diabetes Care 3
• The American College of Cardiology suggests that patients on diuretics should be monitored for signs of volume depletion or hypotension after dose escalation 1